secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096362
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical Q2 net loss $3.2M; first commercial QUELIMMUNE sales in July
----------------------------------------------------------------------------

- Net loss $3.2M ($1.03/share) vs $2.4M ($4.10/share) in Q2 2023, driven by higher R&D and G&A.
- First commercial sales of QUELIMMUNE for pediatric AKI in July 2024; launched with U.S. distribution partner.
- Adult NEUTRALIZE-AKI trial enrolled 42 subjects at 9 sites; CMS granted Category B coverage for Medicare/Medicaid.
- Completed $10M registered direct offering in July; cash ~$6.9M as of July 31 after reducing debt by $2.7M.
- Board expanded with three new directors; expects adult PMA approval in H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000095017024096362/0000950170-24-096362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000095017024096362/icu-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer